An observational study in Cardiac Amyloidosis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.
Sponsored by University Hospital, Strasbourg, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2024, is one of 12 observational ones, reaches primary completion later than 3 of the 15 other live ones, and was the 32nd registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in France, United States, Argentina and 21 more countries
Ages 18–75
Gérond'if · Sites in France
Ages 80+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 233 across 92 observational studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 128 across the 23 interventional studies, 175 across the 12 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 1 study filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
5 of the studies in Amyloid Neuropathies, Familial with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103943Centre Hospitalier Régional d'OrléansAmyloidosis TTR Flow Reserve Evaluation | 2026-12-11 |
| NCT04849754GCS Ramsay Santé pour l'Enseignement et la RechercheAnalysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy | 2026-12-31 |
| NCT04535349University Hospital, CaenQuantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis | 2027-06-15 |
| NCT05101304Saving Lives MattersRegistre HEAR, Healthcare European Amyloidosis Registry | 2027-06-30 |
| NCT06427304Gérond'ifCardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure | 2027-07-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In 2024, the prevalence of TTR cardiac amyloidosis is difficult to determine precisely. Indeed, the disease has long been underdiagnosed due to a lack of effective treatment and non-invasive diagnostic methods. The prevalence of ATTRwt is estimated at 155 to 191 cases per million person-years, with an incidence of 36 cases per million person-years. Both incidence and prevalence increase with age.
The most common presentation of TTR cardiac amyloidosis is heart failure with preserved ventricular ejection fraction (LVEF).
The natural history of TTR cardiac amyloidosis is progression to restrictive heart disease with all the complications described above.
The median time between diagnosis and the first cardiac symptoms was 39 months. Currently, the median survival in France is approximately 3.5 years, but survival appears to be improving, with a mortality rate of 73.5% at 30 months between 2002 and 2006, compared to 15% at 60 months between 2017 and 2022.
The number of patients diagnosed with TTR cardiac amyloidosis appears to be increasing. The overwhelming majority of available data concerns patients treated in cardiology. However, the issue of TTR cardiac amyloidosis concerns all specialists caring for patients with heart failure, particularly in internal medicine due to the high number of admissions from emergency departments, with a significant proportion of patients suffering from cardiac decompensation.
Sujet majeur (≥18 ans) avec un diagnostic d'amylose à TTR
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Describe the number of cases of transthyretin (TTR) cardiac amyloidosis referred to internal medicine between 2013 and 2023.
Time frame: Up to 10 years
Started Apr 2024 (actual). Primary completion is estimated for Dec 2025, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial →
University Hospital, Strasbourg, France →